Our brains exist in a dynamic state of constant change. Most changes are routine or benign, such as normal aging or daily fluctuations in performance. However, others run deeper, driven by processes that gradually affect how brain cells communicate and function, falling under the umbrella of neurodegeneration.
Neurodegeneration is the progressive degradation of brain structure and function, driven by biological processes that impair the brain’s ability to communicate, adapt, and regenerate.
Many of these pathological pathways, including those involving inflammation, metabolic dysfunction, oxidative stress, and synaptic loss, are increasingly recognized as biologically modifiable with early, targeted intervention.
Of course, not every forgetful moment, creative block, or foggy day signals neurodegeneration, but awareness is nevertheless critical to develop healthier, happier brains.
Describing and Defining Neurodegeneration
Neurodegeneration is a catch-all term for the progressive loss of structure and function in brain cells. It affects memory, cognition, movement, and behavior, depending on which brain regions are involved.
One individual might first notice changes in memory or attention. Another person might experience mood changes. A third might develop movement problems. The presenting symptoms vary, yet the underlying biology often follows recognizable patterns (Chen et al., 2021).
A key challenge lies in determining when a change is temporary – such as fatigue and sluggishness from, say, poor sleep or stress – and when it reflects something more persistent and progressive.
Distinguishing between normal fluctuations in brain performance and the earlier stages of neurodegeneration is one of the most critical topics in neuroscience today.
The Four Core Biological Processes of Neurodegeneration
Neurodegenerative diseases exhibit distinct hallmark pathologies and symptoms, yet they often share biological roots.
These include protein buildup, problems with energy production, chronic inflammation, and the brain’s reduced ability to clear away waste. Together, they can gradually wear down the brain’s ability to function (Henrich et al., 2023; Nixon, 2024; Wilson & Vendruscolo, 2023).
- Protein Buildup: Ordinarily, proteins inside brain cells efficiently fold into precise shapes that let them do their jobs. When those shapes are negatively affected, proteins can stick together and form clumps that disrupt communication between cells – a defining feature of diseases like Alzheimer’s, Parkinson’s, and ALS (Soto & Pritzkow, 2018; Wilson & Vendruscolo, 2023).
- Energy Failure: Brain cells require vast quantities of energy. When their mitochondria – the parts of the cell that produce that energy – start to falter, neurons struggle to maintain balance and become more vulnerable to stress (Henrich et al., 2023; Bustamante-Barrientos et al., 2023).
- Chronic Inflammation: The brain’s immune cells, called microglia and astrocytes, are meant to protect neurons. But when they remain switched on for too long, they release molecules that cause damage rather than repair (Gao et al., 2023).
- Slower Waste Clearance: Healthy neurons constantly recycle and remove waste products and damaged material. When this cleanup process slows, waste builds up inside the cell, adding to the stress that drives further decline (Nixon 2024; Rubinsztein et al., 2024).
These four processes may form a vicious circle. Protein clumps damage mitochondria, faulty energy production fuels inflammation, and inflammation further weakens the brain’s cleanup systems.
What We Understand About Specific Diseases
The above four processes – protein aggregation, mitochondrial dysfunction, neuroinflammation, and impaired clearance – are common across neurodegenerative diseases. However, there are still broad variations across specific neurodegenerative diseases.
Alzheimer's Disease
Alzheimer’s disease, forecast to affect some 150 million people by 2050, begins years before memory loss or confusion appears. In the brain, a protein fragment called beta-amyloid begins to accumulate, forming sticky plaques between neurons.
This appears to set off a chain reaction. Inside the cells, another protein, tau, begins to twist into tangles; the brain’s immune cells become overactive; and the delicate connections between neurons begin to break down (Hardy & Selkoe, 2002).
Interestingly, the amount of beta-amyloid tends to level off early, often before symptoms emerge.
What continues to spread is tau pathology – and this correlates most closely with the decline in thinking and memory. It suggests that amyloid may spark the disease, but tau and the resulting neuronal damage drive the symptoms (Livingston et al., 2024).
Viewed this way, Alzheimer’s is a network of changes – protein buildup, inflammation, energy failure, and poor waste clearance – all interacting over years, including a considerable period of time before symptoms begin.
This, however, introduces a considerable window during which interventions can have a significant impact, preventing the disease or altering its course. A recent landmark study found that up to 45% of Alzheimer’s cases are still preventable with interventions throughout the life course (Livingston et al., 2024).
Parkinson's Disease
Parkinson’s disease primarily involves the accumulation of alpha-synuclein in brain cells that produce dopamine.
This buildup forms toxic clumps that interfere with cell function and survival (Calabresi, 2023). The resulting loss of dopamine in key brain regions leads to the movement problems that define the disease.
Many of the genes associated with Parkinson’s – such as PINK1, PRKN, and GBA1 – directly affect mitochondrial function and the cell’s ability to clear damaged components. This indicates that energy failure and impaired waste clearance are central features of the disease (Henrich et al., 2023).
The combination of toxic protein buildup, mitochondrial stress, and inflammation drives the progressive loss of dopamine-producing neurons (Henrich et al., 2023; Gao et al., 2023).
Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
In ALS, degeneration begins in motor neurons – the nerve cells that control movement – leading to muscle weakness and paralysis. In FTD, it affects neurons in the frontal and temporal lobes, changing personality, judgment, and language.
Both diseases are now thought to share the same core pathology, involving the misfolding and accumulation of the protein TDP-43 within neurons (Neumann et al., 2006). When TDP-43 leaves its normal location in the nucleus, it disrupts the cell’s ability to regulate RNA, manage energy, and clear waste.
Modifiable Risk Factors: What the Evidence Shows
Neurodegeneration doesn't happen overnight. It develops over years, often decades, through accumulated damage to brain cells and their networks.
The good news is that many of the factors driving this damage are modifiable. Research consistently shows that lifestyle interventions can reduce risk, slow progression, and support brain resilience.
Physical Exercise Targets Energy Production and Inflammation
Exercise directly alters how the brain produces energy and manages inflammation.
When you exercise, your brain increases production of brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and strengthens communication between brain cells (Romero Garavito et al., 2024).
Moderate aerobic activity – around 60–70% of your maximum heart rate for 30–40 minutes, three to four times per week – most effectively stimulates BDNF and promotes new neuron growth in the hippocampus (Ben Ezzdine et al., 2025).
At the cellular level, exercise improves mitochondrial function in both muscle and brain tissue. It enhances energy efficiency and counteracts the metabolic deficits that drive neurodegeneration (Bustamante-Barrientos et al., 2023).
Exercise also helps reverse the decline in BDNF caused by toxic protein aggregates such as amyloid-beta, which disrupt memory formation (Romero Garavito et al., 2024).
Intervention: Engage in moderate aerobic exercise most days of the week if possible to strengthen mitochondrial function and support neuronal growth.
Cognitive Engagement Builds Reserve Capacity
Sustained intellectual activity builds cognitive reserve – the extra neural capacity that maintains function even as damage develops.
Education, complex work, new learning, and curiosity-driven activities strengthen and diversify neural networks. Neuroimaging studies show that structured cognitive training can measurably improve brain structure and connectivity (Matton et al., 2025).
When neurodegeneration occurs, those with greater reserve maintain function longer because their brains have more alternative pathways available.
Intervention: Continue learning and problem-solving throughout adulthood to build and maintain cognitive reserve.
Sleep Clears Toxic Proteins
Sleep provides essential maintenance that cannot be replaced. During deep sleep, the brain’s glymphatic system clears waste products that accumulate during the day, including amyloid-beta and tau.
Sleep deprivation increases tau levels by about 50% and amyloid-beta by 30% in cerebrospinal fluid (Lucey et al., 2019; Holth et al., 2019).
Chronic poor sleep allows these proteins to build up faster than they can be cleared, accelerating the spread of tau pathology in animal models (Holth et al., 2019). The glymphatic system functions primarily during sleep (Xie et al., 2013), making consistent, high-quality rest critical for long-term brain health.
Intervention: Maintain regular sleep patterns and aim for sufficient deep sleep to support nightly clearance of neurotoxic waste.
Social Connection Reduces Inflammatory Stress
Chronic loneliness and social isolation activate stress pathways that promote inflammation and increase neurodegenerative risk. Recent findings suggest that the association between social connection and cognitive decline is comparable in strength to established medical risk factors such as hypertension and diabetes (Popescu et al., 2025).
Social engagement can also reduce neuroinflammation and improve cognitive outcomes (Matton et al., 2025).
Intervention: Sustain regular, meaningful social interaction to reduce inflammatory stress and support cognitive resilience.
Cardiovascular Health Protects Neural Infrastructure
Neurons rely on a constant supply of oxygen and nutrients delivered through the vascular system, which also removes metabolic waste. Damage to blood vessels disrupts these processes and directly contributes to cognitive decline.
The biological overlap between cardiovascular and neurodegenerative disease is well documented.
Type 2 diabetes, for instance, shares mechanisms with Parkinson’s and Alzheimer’s disease, including mitochondrial dysfunction, insulin resistance, vascular injury, and inflammation (Santiago & Potashkin, 2021). Managing blood pressure, lipid levels, and glucose metabolism, therefore, provides direct neuroprotective effects.
Intervention: Monitor and manage cardiovascular risk factors to maintain the vascular support essential for brain health.
Dietary Patterns Influence Multiple Pathways
Dietary habits shape brain aging through metabolic, inflammatory, and vascular pathways. The Mediterranean and MIND diets are both associated with slower cognitive decline in large population studies (Popescu et al., 2025).
Nutrients such as omega-3 fatty acids and polyphenols – found in foods like fish, walnuts, olive oil, and berries – show neuroprotective effects in controlled trials. In contrast, high consumption of ultra-processed foods is consistently linked to poorer cognitive outcomes (Popescu et al., 2025).
Intervention: Emphasize whole foods, including vegetables, fruits, legumes, fish, and olive oil, while limiting ultra-processed foods to support brain health.
Why Combining Interventions Is Most Effective
Interventions don’t act in isolation – they reinforce one another. Exercise improves sleep quality. Better sleep reduces inflammation. Lower inflammation protects cardiovascular health, among other benefits, in a virtuous cycle.
The evidence supports this interconnected model. In the two-year FINGER trial – a multidomain program combining diet, exercise, cognitive training, and vascular risk monitoring – older adults at risk for cognitive decline showed measurable gains in memory, processing speed, and executive function compared to controls (Ngandu et al., 2015).
Additionally, you can start at practically any age and see meaningful benefits. The adult brain retains remarkable plasticity. Interventions introduced even late in life can produce measurable gains in cognitive performance and brain structure (Matton et al., 2025; Popescu et al., 2025).
Still, timing matters. The processes that lead to neurodegeneration begin decades before symptoms appear. Every year spent building healthy patterns compounds. You’re not just preventing decline – you’re building reserve capacity that protects you if damage does occur.
Moving Forward
Neurodegeneration is a long, gradual change in how neurons function, protect themselves, and communicate. And that timeline is exactly what creates leverage.
When risk factors are identified early, many of the upstream drivers can be influenced through targeted interventions – better sleep, regular exercise, cognitive engagement, social connection, vascular risk control, and supportive nutrition.
These actions do not “guarantee” prevention, but they measurably strengthen resilience and can slow or redirect harmful trajectories.
Want to track and improve your cognitive performance? View our brain health solutions.
References
Ben Ezzdine, L., Dhahbi, W., Dergaa, I., Ceylan, H.İ., Guelmami, N., Ben Saad, H., Chamari, K., Stefanica, V., & El Omri, A. (2025). Physical activity and neuroplasticity in neurodegenerative disorders: A comprehensive review of exercise interventions, cognitive training, and AI applications. Frontiers in Neuroscience, 19, 1502417. https://doi.org/10.3389/fnins.2025.1502417
Bustamante-Barrientos, F.A., Méndez-González, V., Aguilar-García, A., Batista-González, C.M., Ortega, L., Luque-Campos, N., Parga, V., García-Beltrán, O., & Bruna, B. (2023). Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells. Journal of Translational Medicine, 21, 493. https://doi.org/10.1186/s12967-023-04493-w
Calabresi, P. (2023). Alpha-synuclein in Parkinson's disease and other synucleinopathies: A review from pathogenesis to disease mechanisms. Cell Death & Disease, 14, 672. https://doi.org/10.1038/s41419-023-06204-x
Chen, Y., Demnitz, N., Yamamoto, S., Yaffe, K., Lawlor, B., & Leroi, I. (2021). Defining brain health: A concept analysis. International Journal of Geriatric Psychiatry, 36(12), 1891–1903. https://doi.org/10.1002/gps.5564
Gao, C., Zhang, L., Chen, Y., Li, X., Li, J., Xu, Y., & Han, Y. (2023). Microglia in neurodegenerative diseases: Mechanism and potential therapeutic targets. Signal Transduction and Targeted Therapy, 8, 359. https://doi.org/10.1038/s41392-023-01588-0
Hardy, J., & Selkoe, D.J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356. https://doi.org/10.1126/science.1072994
Henrich, M.T., Oertel, W.H., Surmeier, D.J., & Geibl, F.F. (2023). Mitochondrial dysfunction in Parkinson's disease—A key disease hallmark with therapeutic potential. Molecular Neurodegeneration, 18, 83. https://doi.org/10.1186/s13024-023-00676-7
Holth, J.K., Fritschi, S.K., Wang, C., Pedersen, N.P., Cirrito, J.R., Mahan, T.E., Finn, M.B., Manis, M., Geerling, J.C., Fuller, P.M., Lucey, B.P., & Holtzman, D.M. (2019). The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science, 363(6429), 880–884. https://doi.org/10.1126/science.aav2546
Livingston, G., Huntley, J., Liu, K.Y., Costafreda, S.G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., Fox, N.C., Ferri, C.P., Gitlin, L.N., Howard, R., Kales, H.C., Kivimäki, M., Larson, E.B., Nakasujja, N., Rockwood, K., Samus, Q., Shirai, K., Singh-Manoux, A., Schneider, L.S., Walsh, S., Yao, Y., Sommerlad, A., & Mukadam, N. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet, 404(10452), 572–628. https://doi.org/10.1016/S0140-6736(24)01296-0
Lucey, B.P., McCullough, A., Landsness, E.C., Toedebusch, C.D., McLeland, J.S., Zaza, A.M., Fagan, A.M., McCue, L., Xiong, C., Morris, J.C., Benzinger, T.L.S., & Holtzman, D.M. (2019). Reduced non-REM sleep is associated with tau pathology in early Alzheimer's disease. Science Translational Medicine, 11(474), eaau6550. https://doi.org/10.1126/scitranslmed.aau6550
Matton, A., Stephen, R., Daniilidou, M., Barbera, M., Alanko, V., Ballin, M., Ford, J., Hemiö, K., Lehtisalo, J., López Rocha, S., Mangialasche, F., Ngandu, T., Rosenberg, A., Saadmaan, G., Udeh-Momoh, C., Uusimäki, K., Solomon, A., & Kivipelto, M. (2025). Mechanisms of interventions targeting modifiable factors for dementia risk reduction. Molecular Neurodegeneration, 20(1), 11. https://doi.org/10.1186/s13024-025-00845-w
van Blitterswijk, M., Mizielinska, S., Hautbergue, G.M., Gendron, T.F.., Hardiman, O., Ravits, J., Isaacs, A.M., & Rademakers, R. (2025). Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: From genetics to therapeutics. The Lancet Neurology, 24(3), 267–283. https://doi.org/10.1016/S1474-4422(25)00026-2
Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., McCluskey, L.F., Miller, B.L., Masliah, E., Mackenzie, I.R., Feldman, H., Feiden, W., Kretzschmar, H.A., Trojanowski, J.Q., & Lee, V.M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133. https://doi.org/10.1126/science.1134108
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., Lindström, J., Mangialasche, F., Paajanen, T., Pajala, S., Peltonen, M., Rauramaa, R., Stigsdotter-Neely, A., Strandberg, T., Tuomilehto, J., Soininen, H., & Kivipelto, M. (2015). A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. The Lancet, 385(9984), 2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
Nixon, R.A. (2024). Mechanisms of waste-clearance dysfunction in neurodegenerative diseases. Nature Reviews Molecular Cell Biology. Advance online publication. https://doi.org/10.1038/s41580-024-00789-3
Popescu, I., Lenain, M., Rovini, E., & Ruthsatz, M. (2025). Lifestyle interventions and innovative approaches for the management of neurodegenerative disorders in older adults—State-of-the-art and future directions. American Journal of Lifestyle Medicine. Advance online publication. https://doi.org/10.1177/15598276251330170
Romero Garavito, A., Díaz Martínez, V., Juárez Cortés, E., Negrete Díaz, J.V., & Montilla Rodríguez, L.M. (2024). Impact of physical exercise on the regulation of brain-derived neurotrophic factor in people with neurodegenerative diseases. Frontiers in Neurology, 15, 1505879. https://doi.org/10.3389/fneur.2024.1505879
Rubinsztein, D.C., Korolchuk, V.I., & Ktistakis, N.T. (2024). Mechanisms of autophagosome biogenesis. Current Biology, 34(9), R402–R415. https://doi.org/10.1016/j.cub.2024.03.051
Santiago, J.A., & Potashkin, J.A. (2021). The impact of disease comorbidities in Alzheimer's disease. Frontiers in Aging Neuroscience, 13, 631770. https://doi.org/10.3389/fnagi.2021.631770
Soto, C., & Pritzkow, S. (2018). Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nature Neuroscience, 21(10), 1332–1340. https://doi.org/10.1038/s41593-018-0235-9
Wang, W., Wang, L., Lu, J., Siedlak, S.L., Fujioka, H., Liang, J., Jiang, S., Ma, X., Jiang, Z., da Rocha, E.L., Sheng, M., Choi, H., Lerou, P.H., Li, H., & Wang, X. (2016). The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nature Medicine, 22(8), 869–878. https://doi.org/10.1038/nm.4130
Wilson, M.R., & Vendruscolo, M. (2023). Extracellular protein homeostasis in neurodegenerative diseases. Nature Reviews Neuroscience, 24(11), 681–693. https://doi.org/10.1038/s41582-023-00786-2
Xie, L., Kang, H., Xu, Q., Chen, M.J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D.J., Nicholson, C., Iliff, J.J., Takano, T., Deane, R., & Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373–377. https://doi.org/10.1126/science.1241224
